Mapping Hong Kong’s Atlas

Rooted in the broader project of representing Hong Kong through the visual and literary arts, the Hong Kong Atlas book series seeks to build a set of heritage-based networks through a literary series consisting primarily of paperback and digital editions, including bilingual poetry collections. The individual voices of the authors and translators combine to reorient the complexities of memory in relation to Hong Kong’s constantly shifting pasts

Selection Bias in the NBA Draft

Thesis advisor: Christopher MaxwellIn this paper I present an econometric analysis of selection bias in the NBA Draft from 1995-2003. Employing an interval regression maximum likelihood control model that predicts the eventual value of players based on their Draft position, I pinpoint which groups of players consistently over-perform or under-perform relative to their Draft position. Using this analysis I detect bias pertaining to four different groups of players. There was a bias against high school players, especially those taken in the lottery (the top of the first round of the Draft), which may point to risk-averse tendencies of NBA teams. There was also a bias in favor of centers taken in the lottery, who were consistently drafted too high. Black players were selected too low in the first round, and too high in the second round. The final effect deals with foreign entrants to the Draft. From 1995-2001 foreigners were drafted too low; in 2002 and 2003, when more foreigners were selected, they were drafted too high. My paper details the nature of these biases and analyzes their potential causes.Thesis (BA) — Boston College, 2008.Submitted to: Boston College. College of Arts and Sciences.Discipline: Economics.Discipline: Economics Honors Program.Discipline: College Honors Program

Evaluation of Ice-Melting Capacities of Deicing Chemicals

Common deicing chemicals include sodium chloride, magnesium chloride, calcium chloride, calcium magnesium acetate, potassium acetate, potassium formate, and corn or beet-based deicer solution. Liquid deicers are commonly used for pre-wetting road salt, sand or other solid deicers, or mixed with salt brine as liquid deicer. Although manufacturers provide performance data under specific conditions, a standardized test is very much needed. Samples of sodium chloride, magnesium chloride, calcium chloride, potassium acetate, and beet juice-based chemical deicers were selected for performance evaluation. The SHRP Ice-Melting Capacity Test has been used in many research projects, but the results do not always correlate well with field data. A simple and economical test has been developed to evaluate the ice-melting capacities of deicing chemicals using a martini shaker, which shows some potential to become a standardized test for ice-melting capacity evaluation. Field data was collected by the Nebraska Dept. of Roads using automatic vehicle location (AVL) and the maintenance decision support system (MDSS) installed on some plow trucks. The AVL takes roadway pictures from the cab and records vehicle location. The MDSS collects weather data from area weather stations. Although initial shaker test results correlate well with known deicer performance and limited field data provided by MDSS, further development work is necessary before the shaker test can be considered for official use

Evaluation of Ice-Melting Capacities of Deicing Chemicals

Common deicing chemicals include sodium chloride, magnesium chloride, calcium chloride, calcium magnesium acetate, potassium acetate, potassium formate, and corn or beet-based deicer solution. Liquid deicers are commonly used for pre-wetting road salt, sand or other solid deicers, or mixed with salt brine as liquid deicer. Although manufacturers provide performance data under specific conditions, a standardized test is very much needed. Samples of sodium chloride, magnesium chloride, calcium chloride, potassium acetate, and beet juice-based chemical deicers were selected for performance evaluation. The SHRP Ice-Melting Capacity Test has been used in many research projects, but the results do not always correlate well with field data. A simple and economical test has been developed to evaluate the ice-melting capacities of deicing chemicals using a martini shaker, which shows some potential to become a standardized test for ice-melting capacity evaluation. Field data was collected by the Nebraska Dept. of Roads using automatic vehicle location (AVL) and the maintenance decision support system (MDSS) installed on some plow trucks. The AVL takes roadway pictures from the cab and records vehicle location. The MDSS collects weather data from area weather stations. Although initial shaker test results correlate well with known deicer performance and limited field data provided by MDSS, further development work is necessary before the shaker test can be considered for official use

Heat-induced alterations in cashew allergen solubility and IgE binding

AbstractCashew nuts are an increasingly common cause of food allergy. We compare the soluble protein profile of cashew nuts following heating. SDS-PAGE indicate that heating can alter the solubility of cashew nut proteins. The 11S legumin, Ana o 2, dominates the soluble protein content in ready to eat and mildly heated cashew nuts. However, we found that in dark-roasted cashew nuts, the soluble protein profile shifts and the 2S albumin Ana o 3 composes up to 40% of the soluble protein. Analysis of trypsin-treated extracts by LC/MS/MS indicate changes in the relative number and intensity of peptides. The relative cumulative intensity of the 5 most commonly observed Ana o 1 and 2 peptides are altered by heating, while those of the 5 most commonly observed Ana o 3 peptides remaine relatively constant. ELISA experiments indicate that there is a decrease in rabbit IgG and human serum IgE binding to soluble cashew proteins following heating. Our findings indicate that heating can alter the solubility of cashew allergens, resulting in altered IgE binding. Our results support the use of both Ana o 2 and Ana o 3 as potential cashew allergen diagnostic targets

Screening of Multiple Potential Control Genes for use in Caste and Body Region Comparisons Using RT-qPCR in Coptotermes formosanus

Formosan subterranean termites, Coptotermes formosanus, are a significant worldwide pest. Molecular gene expression is an important tool for understanding the physiology of organisms. The recent advancement of molecular tools for Coptotermes formosanus is leading to the advancement of the understanding of termite physiology. One of the first steps in analyzing gene expression is the normalization to constant reference genes. Stable reference genes that have constant expression across multiple treatments are important for accurately comparing target genes' expression. The objective of this investigation was to analyze and validate a set of potential reference genes including 8SrRNA; Glyceraldehyde 3-phosphate dehydrogenase (Gadphd); ribosomal protein L7 (RPL); β-actin (BA1); α-tubulin (Atube); α-actin (Aactin); and elongation factor (Elong) as standards for analysis of transcriptional changes in the termite Coptotermes formosanus, across two phenotypic castes, body regions, and colonies. We also compared the expression of hexamerin-1 and 2 using stable and unstable reference genes to demonstrate the importance of consistent control genes. Our results demonstrate that 18S and RPL can serve as reliable expression standards when comparing these different castes and body regions, and we show that C. formosanus Hex-1 and Hex-2 have expression patterns similar to that previously described in R. flavipes

Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt

Nut-based milks and yogurts are gaining popularity, but may not offer the same benefits as dairy yogurts to consumers. Cashew nuts often cause severe allergic reactions, and cashew nut allergens are stable to several types of processing. To compare its characteristics to dairy yogurt and characterize the effects of fermentation on the Ana o 1-3 cashew nut allergens, a commercial yogurt made from cashew nuts (Cashewgurt) was evaluated for microbiological, physiochemical, and immunological properties. Average counts for lactobacilli and Streptococcus thermophilus were greater than 10 million colony forming units per milliliter, indicating the capacity to provide a health benefit. Cashewgurt pH and viscosity values were comparable to cow milk yogurts, and it was off white in color. SDS-PAGE analysis indicated a clear reduction in Ana o 1 and 2, and immuno-assay with polyclonal anti-cashew IgG antibody and cashew-allergic IgE indicated an overall reduction in allergen content. In contrast, SDS-PAGE, mass spectrometry, immunoblot, and ELISA all revealed that Ana o 3 was relatively unaffected by the fermentation process. In conclusion, Ana o 1 and Ana o 2 are sensitive to degradation, while Ana o 3 survives lactic acid bacterial fermentation during yogurt production. The analysis presented here indicates that cashew nut yogurt is not suitable for those with cashew nut allergy

Generation of long‐lasting light with inductively‐coupled plasma drivers

In order to develop a longer‐lasting source of light, we first decided to use an inductively‐coupled plasma driver to generate the light. We investigated an existing industrial application of this concept. Then we determined the best driver configuration for the plasma light source and the best way to inductively couple the driver to the plasma. After determining the component values appropriate for our design, we simulated it in PSpice 9.1 in order to verify our design. We built an inductively‐coupled plasma driver in hardware to match our design and retrofitted an existing fluorescent light bulb to it. The inductively coupled plasma driver successfully energized the plasma inside the fluorescent light bulb, producing a substantial amount of light. Because this lighting method does not involve electrodes, which degrade over time, inductively‐coupled plasma drivers are a means of generating long‐lasting light

Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise

Circulating levels of undercarboxylated and bioactive osteocalcin double during aerobic exercise at the time levels of insulin decrease. In contrast, circulating levels of osteocalcin plummet early during adulthood in mice, monkeys, and humans of both genders. Exploring these observations revealed that osteocalcin signaling in myofibers is necessary for adaptation to exercise by favoring uptake and catabolism of glucose and fatty acids, the main nutrients of myofibers. Osteocalcin signaling in myofibers also accounts for most of the exercise-induced release of interleukin-6, a myokine that promotes adaptation to exercise in part by driving the generation of bioactive osteocalcin. We further show that exogenous osteocalcin is sufficient to enhance the exercise capacity of young mice and to restore to 15-month-old mice the exercise capacity of 3-month-old mice. This study uncovers a bone-to-muscle feedforward endocrine axis that favors adaptation to exercise and can reverse the age-induced decline in exercise capacity

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen